Michael Clausen-Roost

Vejle, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Journal: Journal for immunotherapy of cancer

Published: June 10, 2026

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial.

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial.

Journal: Blood

Published: March 25, 2026

Validation of US Consensus Eligibility Criteria for Front-Line DLBCL Trials.

Validation of US Consensus Eligibility Criteria for Front-Line DLBCL Trials.

Journal: European journal of haematology

Published: July 17, 2025

International Prognostic Models as Tools for Selection of Higher-risk Trial-eligible Patients With Diffuse Large B-Cell lymphoma.

International Prognostic Models as Tools for Selection of Higher-risk Trial-eligible Patients With Diffuse Large B-Cell lymphoma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 24, 2025

Outcome of T-cell/histiocyte-rich large B-cell lymphoma-A Danish nationwide matched cohort study.

Outcome of T-cell/histiocyte-rich large B-cell lymphoma-A Danish nationwide matched cohort study.

Journal: British journal of haematology

Published: June 10, 2025

Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20×CD3 antibodies.

Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20×CD3 antibodies.

Journal: Blood neoplasia

Published: December 02, 2024

Validation of prognostic models in elderly patients with diffuse large B-cell lymphoma in a real-world nationwide population-based study - development of a clinical nomogram.

Validation of prognostic models in elderly patients with diffuse large B-cell lymphoma in a real-world nationwide population-based study - development of a clinical nomogram.

Journal: Annals of hematology

Published: October 08, 2024

A Real-World Data-Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B-Cell Lymphoma Patients.

A Real-World Data-Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B-Cell Lymphoma Patients.

Journal: European journal of haematology

Published: May 21, 2024

Revisiting beta-2 microglobulin as a prognostic marker in diffuse large B-cell lymphoma.

Revisiting beta-2 microglobulin as a prognostic marker in diffuse large B-cell lymphoma.

Journal: Cancer medicine

Published: January 12, 2024

Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models.

Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models.

Journal: Blood cancer journal

Published: July 09, 2023

Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group.

Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group.

Journal: American journal of hematology

Published: May 23, 2022

Showing 1-11 of 11

Last Updated: 09/26/2026